Dataset Information

Distinction of cardiometabolic profiles among people ?75?years with type 2 diabetes: a latent profile analysis.

ABSTRACT:

Background

Older patients with type 2 diabetes mellitus represent a heterogeneous group in terms of metabolic profile. It makes glucose-lowering-therapy (GLT) complex to manage, as it needs to be individualised according to the patient profile. This study aimed to identify and characterize subgroups existing among older patients with diabetes.

Methods

Retrospective observational cohort study of outpatients followed in a Belgian diabetes clinic. Included participants were all aged ?75?years, diagnosed with type 2 diabetes, Caucasian, and had a Homeostasis Model Assessment (HOMA2). A latent profile analysis was conducted to classify patients using the age at diabetes diagnosis and HOMA2 variables, i.e. insulin sensitivity (HOMA2%-S), beta-cell-function (HOMA2%-?), and the product between both (HOMA2%-?xS; as a measure of residual beta-cell function). GLT was expressed in defined daily dose (DDD).

Results

In total, 147 patients were included (median age: 80?years; 37.4% women; median age at diabetes diagnostic: 62?years). The resulting model classified patients into 6 distinct cardiometabolic profiles. Patients in profiles 1 and 2 had an older age at diabetes diagnosis (median: 68?years) and a lesser decrease in HOMA2%-S, as compared to other profiles. They also presented with the highest HOMA2%-?xS values. Patients in profiles 3, 4 and 5 had a moderate decrease in HOMA2%-?xS. Patients in profile 6 had the largest decrease in HOMA2%-? and HOMA2%-?xS. This classification was associated with significant differences in terms of HbA1c values and GLT total DDD between profiles. Thus, patients in profiles 1 and 2 presented with the lowest HbA1c values (median: 6.5%) though they received the lightest GLT (median GLT DDD: 0.75). Patients in profiles 3 to 5 presented with intermediate values of HbA1c (median: 7.3% and GLT DDD (median: 1.31). Finally, patients in profile 6 had the highest HbA1c values (median: 8.4%) despite receiving the highest GLT DDD (median: 2.28). Other metabolic differences were found between profiles.

Conclusions

This study identified 6 groups among patients ?75?years with type 2 diabetes by latent profile analysis, based on age at diabetes diagnosis, insulin sensitivity, absolute and residual ?-cell function. Intensity and choice of GLT should be adapted on this basis in addition to other existing recommendations for treatment individualisation.

SUBMITTER: Christiaens A

PROVIDER: S-EPMC6683451 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Distinction of cardiometabolic profiles among people ≥75 years with type 2 diabetes: a latent profile analysis.

Christiaens Antoine A Hermans Michel P MP Boland Benoit B Henrard Séverine S

BMC endocrine disorders 20190805 1

<h4>Background</h4>Older patients with type 2 diabetes mellitus represent a heterogeneous group in terms of metabolic profile. It makes glucose-lowering-therapy (GLT) complex to manage, as it needs to be individualised according to the patient profile. This study aimed to identify and characterize subgroups existing among older patients with diabetes.<h4>Methods</h4>Retrospective observational cohort study of outpatients followed in a Belgian diabetes clinic. Included participants were all aged ...[more]

PMID: 31382941

Similar Datasets

Project description:Importance:Among older individuals with type 2 diabetes, those with poor health have greater risk and derive less benefit from tight glycemic control with insulin. Objective:To examine whether insulin treatment is used less frequently and discontinued more often among older individuals with poor health compared with those in good health. Design, Setting, and Participants:This longitudinal cohort study included 21?531 individuals with type 2 diabetes followed for up to 4 years starting at age 75 years. Electronic health record data from the Kaiser Permanente Northern California Diabetes Registry was collected to characterize insulin treatment and glycemic control over time. Data were collected from January 1, 2009, through December 31, 2017, and analyzed from February 2, 2018, through June 30, 2019. Exposures:Health status was defined as good (<2 comorbid conditions or 2 comorbidities but physically active), intermediate (>2 comorbidities or 2 comorbidities and no self-reported weekly exercise), or poor (having end-stage pulmonary, cardiac, or renal disease; diagnosis of dementia; or metastatic cancer). Main Outcomes and Measures:Insulin use prevalence at age 75 years and discontinuation among insulin users over the next 4 years (or 6 months prior to death if <4 years). Results:Of 21?531 patients, 10?396 (48.3%) were women, and the mean (SD) age was 75 (0) years. Nearly one-fifth of 75-year-olds (4076 [18.9%]) used insulin. Prevalence and adjusted risk ratios (aRRs) of insulin use at age 75 years were higher in individuals with poor health (29.4%; aRR, 2.03; 95% CI, 1.87-2.20; P?<?.01) and intermediate health (27.5%; aRR, 1.85; 95% CI, 1.74-1.97; P?<?.01) relative to good health (10.5% [reference]). One-third (1335 of 4076 [32.7%]) of insulin users at age 75 years discontinued insulin within 4 years of cohort entry (and at least 6 months prior to death). Likelihood of continued insulin use was higher among individuals in poor health (aRR, 1.47; 95% CI, 1.27-1.67; P?<?.01) and intermediate health (aRR, 1.16; 95% CI, 1.05-1.30; P?<?.01) compared with good health (reference). These same prevalence and discontinuation patterns were present in the subset with tight glycemic control (hemoglobin A1c <7.0%). Conclusions and Relevance:In older individuals with type 2 diabetes, insulin use was most prevalent among those in poor health, whereas subsequent insulin discontinuation after age 75 years was most likely in healthier patients. Changes are needed in current practice to better align with guidelines that recommend reducing treatment intensity as health status declines.